Wat zijn de openingstijden?

Maandag 09:00 - 17:00 Dinsdag 09:00 - 17:00 Woensdag 09:00 - 17:00 Donderdag 09:00 - 17:00 Vrijdag 09:00 - 17:00

MILabs

Name: MILabs
Address: Houten, 3991CD, NL
Telephone: +31887565343

We provide high-end molecular imaging solutions for biomedical research. Today these systems contribu

Science-based, science serving
MILabs was founded in 2006 by Professor Frederik Beekman, who – as a researcher in molecular imaging – designed a whole new line of molecular imaging systems with unsurpassed resolution. MILabs’ U-SPECT and VECTor technologies have received many international awards from the scientific community. Unmatched qualities
MILabs’ first commercial successes with U-SPECT-II

and U-SPECT-II/CT were followed by rapid expansion of the company’s customer base throughout the world. There have been several new developments that further improved the performance and functionality of the imaging systems. In 2010 MILabs introduced an extremely user friendly, fully integrated simultaneous SPECT and PET imaging device with sub-mm resolution: VECTor. Best choice in combined SPECT/PET/CT
VECTor is based on MILabs´ proprietary multi-pinhole technologies for ultra-high resolution imaging of gamma emitting isotopes up to 511 KeV and is fully integrated in one single platform. In many user relevant applications VECTor surpasses the performance (in resolution, flexibility and speed) of existing technologies such as coincidence-based PET and tri-modality devices. User friendly, customized configurations and cost-effective
An integral part of MILabs imaging system is a patented and specially designed user interface that provides simple, intuitive system operation and highly efficient workflow. Our systems are built in different base configurations to best meet the researcher’s wishes, offering both exceptional value and cost-effectiveness. System configurations may vary based upon collimator selection, third party accessories required, or the addition of a specially integrated CT scanner.

14/03/2023

Meet us at EMIM 2023, the European Molecular Imaging Meeting.

https://www.milabs.com/calendar/
https://e-smi.eu/meetings/emim/emim-2023/

10/03/2023

NEW INSIGHTS INTO KEY MECHANISMS OF siRNA-LNP BIODISTRIBUTION

Hepatic clearance of lipid nanoparticles (LNP) carrying encapsulated nucleic acids restricts their therapeutic applicability. This study focused on investigating a tool for regulating this hepatic clearance, modifying the LNP biodistribution, and increasing their uptake in the liver. Here a 3D integrated optical imaging unit (U-CT/OI) was used to perform fluorescence tomography (FLT) to assess the in vivo biodistribution of Cy7-labeled siRNA-LNP, studying how this is affected by the presence of the leukotriene B4 receptor inhibitor (BLT1i).
This work proves that the balance in the biodistribution of siRNA-LNP between immune cells and liver parenchymal cells can be modified with small molecules.

Publication in Advanced Healthcare Materials:
https://onlinelibrary.wiley.com/doi/full/10.1002/adhm.202202670
Used imaging platform: https://www.milabs.com/milabs-movies/

-CT -OI

08/03/2023

Meet us at ESMI’s annual meeting – the European Molecular Imaging Meeting – EMIM 2023, March 14-17, and discover our preclinical imaging solutions. In addition, join the MILabs Lunch Symposium on March 15, starting at 12.15 pm, and learn about exciting features and applications of MILabs imaging systems.

20/02/2023

IDENTIFYING A NEW PATHWAY FOR EFFICIENT DISTRIBUTION OF NANOPARTICLES IN THE BRAIN USING ULTRA HIGH-RESOLUTION SPECT/CT
Nanoparticles (NPs) have a high potential for the treatment of central nervous system (CNS) disorders, but the blood-brain barrier (BBB) restricts access to the CNS. Their direct cerebrospinal fluid (CSF) administration bypasses the BBB endothelium but still fails to give adequate brain uptake. Here, a novel approach for CNS delivery of 111In-radiolabelled gold nanoparticles via intra-cisterna magna administration was developed and validated in vivo by tracking the nanoparticles using an VECTor PET/SPECT/CT system with advanced software for precise 111In quantification.
The intracisternal administration of nanoparticles in conjunction with systemic hypertonic saline enhanced their global CNS delivery. It dramatically increased the parenchymal NPs uptake, especially in deep brain regions, proving that the glymphatic-assisted perivascular delivery is a pathway for highly efficient brain-wide distribution of small NPs.

Publication in Journal of Controlled Release: https://www.sciencedirect.com/science/article/pii/S0168365923000639
Used imaging platform: https://www.milabs.com/milabs-movies/

-brainbarrier

07/02/2023

Due to the complexity and heterogeneity of cancer, clear and accurate tumor imaging and image-guided multimodal synergistic therapy are highly in demand. In this work, the use of modified bismuth-based mesoporous-silica-coated nanoparticles (BMSNs) in CT cancer imaging and image-guided synergistic photothermal chemotherapy was investigated. An MILabs U-CT system was used for the validation in vivo of the CT imaging enhancing the capabilities of such nanoparticles.
This work demonstrates that tumor-homing peptides can guide nanoparticles to tumors and allow the nanoparticles to enhance cancer imaging and photothermal/chemo combination therapy.
Publication in Advanced Optical Materials: https://onlinelibrary.wiley.com/doi/abs/10.1002/adom.202201482
Used imaging platform: https://www.milabs.com/milabs-movies/

24/01/2023

DYE LABELING FOR OPTICAL IMAGING BIASES DRUG CARRIERS' BIODISTRIBUTION AND TUMOR UPTAKE

The influence of different NIRF dyes on the pharmacokinetics, biodistribution, and tumor cell uptake of pHPMAsnanocarriers was investigated in vivo in mice using fluorescence tomography (FLT) on an MILabs Optical Tomography system (OI/CT).
Dyes' hydrophilicity was shown to strongly influence tumor cell uptake of free dyes as well as the uptake of labeled pHPMA. Furthermore, the free dyes had significantly different biodistribution profiles and elimination pathways, which also influenced the in vivo behavior of labeled pHPMA. Thus, careful selection of dye tags for non-invasive optical imaging is important to avoid misinterpretations of function, biodistribution, and performance of nanocarriers or biomolecules.

Published in Nanomedicine: Nanotechnology, Biology and Medicine: https://www.sciencedirect.com/science/article/abs/pii/S1549963423000011?via%3Dihub
Used imaging platform: https://www.milabs.com/milabs-movies/

/CT

19/01/2023

FULLY HUMAN IMMUNO-PET IMAGING PROBE FOR OVARIAN AND PANCREATIC CANCERS

A new immuno-PET imaging probe was developed from a fully human monoclonal antibody to detect ovarian and pancreatic cancers. [89Zr] was used as a label to investigate in vivo stability, biodistribution, and specific tumor affinity in mice using an MILabs imaging instrument.
It was shown that this new probe was stable in serum and showed specific uptake and retention in tumor xenografts even after 120 h p.i., bounding specifically to MUC16-expressing cancer cells.
Such a new ligand was demonstrated to be an effective non-invasive imaging probe for ovarian and pancreatic cancers, and it shows promise for further development of theranostic radiopharmaceuticals.

Publication in Pharmaceutics: https://www.mdpi.com/1999-4923/14/12/2824
Used imaging platform: https://www.milabs.com/milabs-movies/

10/01/2023

FAP-TARGETED RADIOLIGAND THERAPY FOR SOLID TUMORS TREATMENT
Fibroblast activation protein (FAP) has received increasing attention as an oncological target because of its prominent expression in solid tumors but virtual absence from healthy tissues.
A new FAP-targeted radioligand therapy (RLT) comprised of a FAP6 ligand conjugated to DOTA and an albumin-binder for enhanced pharmacokinetics was developed by Purdue University and its performance was evaluated in vivo in four different murine tumor models using an MILabs imaging instrument. This new radioligand demonstrated high affinity for FAP, prolonged circulation, strong accumulation in tumors, and significant suppression of tumor growth when radiolabeled with lutetium-177, proving that it constitutes a promising candidate for FAP-targeted RLT of solid tumors.

Publication in Journal of Nuclear Medicine:
https://jnm.snmjournals.org/content/early/2022/12/08/jnumed.122.264494
Used scanner: VECTor+CT model 2014.
VECTorCT platform 2022: https://www.milabs.com/milabs-movies/

21/11/2022

We can’t wait to meet you in Chicago at the , Saturday-Wednesday, November 27-30. Visit our booth to discuss your imaging needs.

Adres

Houten
3991CD

Openingstijden

Maandag	09:00 - 17:00
Dinsdag	09:00 - 17:00
Woensdag	09:00 - 17:00
Donderdag	09:00 - 17:00
Vrijdag	09:00 - 17:00

Telefoon

+31887565343

Website

http://www.milabs.com/

Meldingen

Wees de eerste die het weet en laat ons u een e-mail sturen wanneer MILabs nieuws en promoties plaatst. Uw e-mailadres wordt niet voor andere doeleinden gebruikt en u kunt zich op elk gewenst moment afmelden.